TELA Bio, Inc. (NASDAQ:TELA) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET
Company Participants
Louisa Smith – The Gilmartin Group
Antony Koblish – Co-founder, President & Chief Executive Office
Roberto Cuca – Chief Operating Officer & Chief Financial Officer
Conference Call Participants
Frank Takkinen – Lake Street Capital Markets
Michael Sarcone – Jefferies
David Turkaly – Citizens JMP
Operator
Good afternoon ladies and gentlemen and welcome to the TELA Bio First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode. Following the prepared remarks, there will be a question-and-answer session. Please be advised that today’s conference is being recorded.
I would now like to turn the conference over to Louisa Smith from Gilmartin Group.
Louisa Smith
Thank you Gerald and good afternoon everyone. Earlier today, TELA Bio released financial results for the first quarter 2025. A copy of the press release is available on the company’s website. Joining me on today’s call are Tony Koblish, President and Chief Executive Officer; and Roberto Cuca, Chief Operating Officer and Chief Financial Officer.
Before we begin, I’d like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company’s past and future filings with the SEC, including, without limitation, the company’s annual report on Form 10-K and quarterly reports on Form 10-Q which identify the specific factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development and pipeline opportunities, product potential, the impact of various macroeconomic conditions identified in our filings, like changes in surgical procedural volumes, the regulatory environment, sales and marketing strategies, capital resources or operating performance.
With that, I will
